HRP20010714B1 - Kit za radio-obilježavanje i ispitivanje vezivanja - Google Patents

Kit za radio-obilježavanje i ispitivanje vezivanja

Info

Publication number
HRP20010714B1
HRP20010714B1 HR20010714A HRP20010714A HRP20010714B1 HR P20010714 B1 HRP20010714 B1 HR P20010714B1 HR 20010714 A HR20010714 A HR 20010714A HR P20010714 A HRP20010714 A HR P20010714A HR P20010714 B1 HRP20010714 B1 HR P20010714B1
Authority
HR
Croatia
Prior art keywords
antibodies
chelator
patient
further purification
testing kit
Prior art date
Application number
HR20010714A
Other languages
English (en)
Croatian (hr)
Inventor
Chinn Paul
Morena Ronald
Labarre Michael
E. Leonard John
Original Assignee
Idec Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corporation filed Critical Idec Pharmaceuticals Corporation
Publication of HRP20010714A2 publication Critical patent/HRP20010714A2/hr
Publication of HRP20010714B1 publication Critical patent/HRP20010714B1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Packages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HR20010714A 1999-03-01 2000-02-29 Kit za radio-obilježavanje i ispitivanje vezivanja HRP20010714B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay

Publications (2)

Publication Number Publication Date
HRP20010714A2 HRP20010714A2 (en) 2003-02-28
HRP20010714B1 true HRP20010714B1 (hr) 2009-01-31

Family

ID=22984524

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010714A HRP20010714B1 (hr) 1999-03-01 2000-02-29 Kit za radio-obilježavanje i ispitivanje vezivanja

Country Status (35)

Country Link
US (2) US20020102208A1 (cg-RX-API-DMAC7.html)
EP (2) EP2112512B1 (cg-RX-API-DMAC7.html)
JP (1) JP4704570B2 (cg-RX-API-DMAC7.html)
KR (1) KR100729247B1 (cg-RX-API-DMAC7.html)
CN (1) CN1235639C (cg-RX-API-DMAC7.html)
AT (1) ATE433108T1 (cg-RX-API-DMAC7.html)
AU (1) AU776747B2 (cg-RX-API-DMAC7.html)
BG (1) BG65690B1 (cg-RX-API-DMAC7.html)
BR (2) BRPI0017596B8 (cg-RX-API-DMAC7.html)
CA (2) CA2742153C (cg-RX-API-DMAC7.html)
CY (2) CY1109335T1 (cg-RX-API-DMAC7.html)
CZ (2) CZ306959B6 (cg-RX-API-DMAC7.html)
DE (1) DE60042326D1 (cg-RX-API-DMAC7.html)
DK (2) DK2112512T3 (cg-RX-API-DMAC7.html)
EE (1) EE05650B1 (cg-RX-API-DMAC7.html)
ES (2) ES2328100T3 (cg-RX-API-DMAC7.html)
HK (1) HK1045730B (cg-RX-API-DMAC7.html)
HR (1) HRP20010714B1 (cg-RX-API-DMAC7.html)
HU (2) HU230516B1 (cg-RX-API-DMAC7.html)
IL (1) IL145109A0 (cg-RX-API-DMAC7.html)
ME (1) ME00782B (cg-RX-API-DMAC7.html)
MX (1) MXPA01008837A (cg-RX-API-DMAC7.html)
MY (1) MY138674A (cg-RX-API-DMAC7.html)
NO (2) NO329142B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ513788A (cg-RX-API-DMAC7.html)
PL (1) PL205780B1 (cg-RX-API-DMAC7.html)
PT (2) PT2112512E (cg-RX-API-DMAC7.html)
RS (1) RS51778B (cg-RX-API-DMAC7.html)
RU (1) RU2251110C2 (cg-RX-API-DMAC7.html)
SI (2) SI1192463T1 (cg-RX-API-DMAC7.html)
SK (2) SK288096B6 (cg-RX-API-DMAC7.html)
TW (1) TWI294969B (cg-RX-API-DMAC7.html)
UA (1) UA78484C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000052473A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200106943B (cg-RX-API-DMAC7.html)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
EP1383800A4 (en) * 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1638989T3 (da) * 2003-06-25 2008-11-17 Peregrine Pharmaceuticals Inc Fremgangsmåde og apparat til kontinuerlig radiomærkning af proteiner i stor målestok
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
DK1680141T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
EP2312315A1 (en) 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US20080214933A1 (en) * 2005-08-25 2008-09-04 Koninklijke Philips Electronics, N.V. Image-Based Planning Methods and Apparatus for Targeted Therapy
CN104090095B (zh) * 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2008055997A1 (en) * 2006-11-10 2008-05-15 Alphaptose Gmbh Use of tri-substituted glycerol compounds for the treatment of radiation injuries
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
WO2009080541A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
AU2008359583B2 (en) 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010043977A2 (en) 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
EP3117709B1 (en) 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
CN103237902A (zh) * 2010-08-13 2013-08-07 Rdm企业股份有限公司 减少糖的颜色的方法和组合物
PT3045183T (pt) 2011-03-11 2018-11-02 Genzyme Corp Apelina peguilada e suas utilizações
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
KR102149069B1 (ko) 2012-03-20 2020-08-28 후맙스 바이오메드 에스에이 Rsv, mpv 및 pvm를 중화하는 항체 및 이의 용도
WO2013148296A1 (en) 2012-03-28 2013-10-03 Sanofi Antibodies to bradykinin b1 receptor ligands
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
EP2872894B1 (en) * 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US9580511B2 (en) 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
BR112016002753A2 (pt) 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
JP6156962B2 (ja) 2014-02-27 2017-07-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム エキソソームを単離するための方法および組成物
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
KR102731863B1 (ko) 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
US12214038B2 (en) 2014-07-22 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
EP3831404B1 (en) 2014-11-18 2026-01-28 Humabs Biomed S.A. Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
ES2947824T3 (es) 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
US10278438B2 (en) 2015-08-31 2019-05-07 Grabbies Media, Llc Consumer usable device with redeemable member
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
CA3000167A1 (en) 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン,エルエルシー A型インフルエンザを治療する方法
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
JP7246320B2 (ja) 2017-05-05 2023-03-27 バクシネックス インコーポレーティッド ヒト抗セマフォリン4d抗体
KR20200038481A (ko) 2017-07-19 2020-04-13 호프만 테크놀로지스, 인크. 스트레스-관련 장애를 치료하기 위한 조성물
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
SI3898668T1 (sl) 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
JP7575401B2 (ja) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータtcr結合ポリペプチド
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
AU2021225962A1 (en) 2020-02-28 2022-10-20 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
EP4164745A1 (en) 2020-06-11 2023-04-19 Vaccinex, Inc. Use of cxcl13 binding molecules to promote peripheral nerve regeneration
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド B型肝炎ウイルス感染を処置するための抗体組成物および方法
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
JP2026513101A (ja) 2022-10-25 2026-04-23 アブリンクス エン.ヴェー. エフェクター機能が強化された糖鎖改変Fc変異ポリペプチド
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025177185A1 (en) * 2024-02-20 2025-08-28 Janssen Biotech, Inc. Materials and methods for biologic affinity analysis
TW202617767A (zh) 2024-06-14 2026-05-01 法商賽諾菲公司 用cd28/ox40雙特異性抗體的實體器官移植受試者的治療
TW202604950A (zh) 2024-07-23 2026-02-01 美商鳥岩生物瑟博公司 肥胖症之治療
WO2026146204A1 (en) 2025-01-03 2026-07-09 Ablynx Nv Compounds, constructs and compositions targeting tnf and ox40l for use in the treatment of type 1 diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011026A2 (en) * 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井 三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
AU593611B2 (en) * 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0484989B1 (en) * 1986-09-05 1996-04-24 GANSOW, Otto A. Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
WO1992011864A1 (en) * 1991-01-11 1992-07-23 Cryopharm Corporation Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
ATE134999T1 (de) * 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2095141A1 (en) 1990-11-05 1992-05-06 Ingegerd Hellstrom Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011026A2 (en) * 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma

Also Published As

Publication number Publication date
TWI294969B (cg-RX-API-DMAC7.html) 2008-03-21
DE60042326D1 (de) 2009-07-16
NO330705B1 (no) 2011-06-20
DK2112512T3 (en) 2014-12-15
US20020102208A1 (en) 2002-08-01
CZ20013126A3 (cs) 2002-07-17
WO2000052473A3 (en) 2002-01-31
CA2362119A1 (en) 2000-09-08
HUP0202522A3 (en) 2011-03-28
CZ306959B6 (cs) 2017-10-11
WO2000052473A2 (en) 2000-09-08
EP2112512A2 (en) 2009-10-28
NO20014245D0 (no) 2001-08-31
CN1345417A (zh) 2002-04-17
BRPI0017596A2 (pt) 2011-09-27
HUP1300275A2 (en) 2002-11-28
HK1045730A1 (en) 2002-12-06
KR100729247B1 (ko) 2007-06-15
CZ303262B6 (cs) 2012-07-04
NZ513788A (en) 2004-03-26
EE05650B1 (et) 2013-04-15
PT2112512E (pt) 2015-01-13
JP4704570B2 (ja) 2011-06-15
MY138674A (en) 2009-07-31
EE200100465A (et) 2002-10-15
DK1192463T3 (da) 2009-10-05
SK287745B6 (sk) 2011-08-04
SK12162001A3 (sk) 2002-12-03
ES2328100T3 (es) 2009-11-10
HK1131208A1 (en) 2010-01-15
HU229627B1 (en) 2014-03-28
BG65690B1 (bg) 2009-06-30
CA2742153C (en) 2015-04-14
RU2251110C2 (ru) 2005-04-27
NO20014245L (no) 2001-10-31
EP1192463B1 (en) 2009-06-03
SI2112512T1 (sl) 2015-02-27
US7608241B2 (en) 2009-10-27
HUP0202522A2 (hu) 2002-11-28
WO2000052473A9 (en) 2001-03-08
ATE433108T1 (de) 2009-06-15
SK288096B6 (sk) 2013-07-02
KR20020021772A (ko) 2002-03-22
BRPI0008719B1 (pt) 2015-07-21
PL205780B1 (pl) 2010-05-31
PT1192463E (pt) 2009-09-10
CY1109335T1 (el) 2014-07-02
ES2526723T3 (es) 2015-01-14
RS51778B (sr) 2011-12-31
BRPI0008719A (pt) 2001-12-26
BRPI0017596B8 (pt) 2023-04-25
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
AU776747B2 (en) 2004-09-23
NO329142B1 (no) 2010-08-30
NZ530868A (en) 2005-12-23
HRP20010714A2 (en) 2003-02-28
MXPA01008837A (es) 2002-05-14
CY1116265T1 (el) 2017-02-08
NO20100717L (no) 2001-10-31
CA2742153A1 (en) 2000-09-08
ZA200106943B (en) 2002-11-22
CN1235639C (zh) 2006-01-11
HK1045730B (zh) 2006-08-18
US20050169838A1 (en) 2005-08-04
HU230516B1 (hu) 2016-10-28
ME00782B (me) 2012-03-20
SI1192463T1 (sl) 2009-10-31
BRPI0017596B1 (pt) 2015-09-01
EP2112512B1 (en) 2014-11-19
EP2112512A3 (en) 2009-12-16
YU61601A (sh) 2004-07-15
AU3505200A (en) 2000-09-21
CA2362119C (en) 2012-12-11
JP2002538179A (ja) 2002-11-12
IL145109A0 (en) 2002-06-30
PL352531A1 (en) 2003-08-25
UA78484C2 (en) 2007-04-10
EP1192463A2 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
Wu Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs
Nachlas et al. The determination of lactic dehydrogenase with a tetrazolium salt
RU2001126400A (ru) Набор для радиоактивного мечения и анализ связывания
Chen et al. Demonstration that mammalian methionine synthases are predominantly cobalamin-loaded
Holmsen et al. Thrombin-induced platelet release reaction and platelet lysosomes
CA2362119A1 (en) Radiolabeling kit and binding assay
CA2362908A1 (en) Kit for radiolabeling proteins with yttrium-90
Goaz et al. Nitrate reduction in whole saliva
DK1017413T3 (da) Flydende formulering af interferon-beta
EP0248887A4 (en) CELL-FREE T-CELL ANTIGUE RECEPTOR AND CLINICAL USE.
EP1489418A4 (en) NEW FLUORESCENT MARKING COMPOUNDS
IL98708A0 (en) Kit for the specific assay of angiotensin ii
CN102368054B (zh) 检测人全血中他克莫司药物浓度的化学发光酶联免疫试剂盒及其化学发光底物显色液
Lee et al. Comparative studies of iodo-bead and chloramine-T methods for the radioiodination of human alpha-fetoprotein
Papavasiliou et al. Thyroid hormonelike actions of 3, 3′, 5′-l-triiodothyronine and 3, 3′-diiodothyronine
Amano et al. Binding of hemoglobin by Porphyromonas gingivalis
Martin et al. Hormonal influences on bone cells
Sraer et al. Evidence for glomerular receptors for parathyroid hormone
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
DE3478958D1 (en) Protein conjugates of penicilloic acid, their preparation and use
Heitz et al. Selective binding of fluorescein mercuric acetate to yeast alcohol dehydrogenase
Mohindru et al. Endogenous copper is cytotoxic to a lymphoma in primary culture which requires thiols for growth
Hayes et al. Radioiodination of sulfhydryl-sensitive proteins
Mitchell et al. Uptake of L-tri-iodothyronine by human cultured trophoblast cells
London Metabolism of hemoglobin and of bile pigment

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: BIOGEN IDEC MA INC., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190107

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200229